Jury Awards $289M to Man Who Blames Roundup for Cancer Print E-mail
Written by FHI's Week in Review   
Monday, 13 August 2018 16:51
AP, via, informs us that Dewayne Johnson, 46, alleged that heavy contact with the herbicide Roundup caused his non-Hodgkin's lymphoma. On August 10 the California Superior Court jury agreed that Roundup contributed to Johnson's cancer and Monsanto, the manufacturer of the herbicide, should have provided a label warning of the potential health hazard. Monsanto has denied a link between the active ingredient in Roundup - glyphosate - and cancer, saying hundreds of studies have established that glyphosate is safe.
Read more in the current issue of Week in Review>>
Last Updated on Monday, 13 August 2018 16:56
Is there a case against shared decision making? Print E-mail
Written by Michel Accad, MD | KevinMD   
Tuesday, 24 July 2018 18:09
In a matter of less than a decade, "shared decision-making" (SDM) has emerged as the uncontested principle that must inform doctor-patient relationships everywhere. Consistently lauded by ethicists and medical academics alike, it has attracted the attention of the government which is now threatening to penalize doctors and patients who do not participate in SDM prior to providing certain treatments, even if the legal process of informed consent has been fulfilled - and even if the treatment is widely considered to be clinically justified.
For example, in a recent issue of JAMA, an editorial approvingly reports that the Center for Medicare and Medicaid Services will soon refuse to pay physicians and hospitals for the implantation of cardioverter-defibrillators unless the decision to implant these life-saving devices was "shared" with the patient. Although the announcement is short on details regarding the formal process by which SDM must be documented to have occurred, the new policy certainly testifies to the unquestioned status SDM has rapidly acquired as a general principle of medical ethics.
Last Updated on Tuesday, 24 July 2018 18:11
Trump administration proposes altering rule on drug rebates Print E-mail
Written by FHI's Week in Review   
Monday, 23 July 2018 13:47

The Trump administration has proposed a rule that would scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers, according to the Office of Management and Budget (OMB) website. Details of the proposed rule have not yet been made public, but its title on the OMB site refers to removing the safe harbor protection for rebates from the anti-kickback law.

Read more in the current issue of Week in Review>>
Last Updated on Monday, 23 July 2018 13:53
Sponsor Showcase Print E-mail
Written by Sponsor   
Tuesday, 17 July 2018 00:00
bdo-ftl-florida-health-industry-ad-9-16 final
Last Updated on Tuesday, 17 July 2018 11:40

Website design, development, and hosting provided by